| Literature DB >> 34987035 |
Yiqi Su1, Haoxuan Li2, Jie Teng3,4, Jiarui Xu5, Yang Li4, Xialian Xu4, Bo Shen4, Wuhua Jiang4, Yimei Wang4, Yi Fang4, Chunsheng Wang6, Zhe Luo7, Xiaoqiang Ding4.
Abstract
OBJECTIVES: Acute kidney injury (AKI) is a common complication of cardiac surgery. This study aimed to explore the effects of hyperuricaemia, being overweight and hyperlipidaemia as risk factors for AKI in patients following cardiac surgery (cardiac surgery-associated acute kidney injury (CSA-AKI)).Entities:
Keywords: acute renal failure; adult nephrology; cardiac surgery
Mesh:
Year: 2022 PMID: 34987035 PMCID: PMC8734032 DOI: 10.1136/bmjopen-2020-047090
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Baseline characteristics of the study population according to uric acid quartiles
| All (=1420) | Q1 (n=351) | Q2 (n=360) | Q3 (n=353) | Q4 (n=356) | P value | |
| Gender (male), n (%) | 833 (58.7) | 127 (36.2) | 207 (57.5) | 231 (65.4) | 272 (76.4) | <0.001 |
| Age (years) | 57.1±12.2 | 56.7±12.5 | 56.9±12.3 | 56.9±12.4 | 57.7±11.5 | 0.877 |
| Body mass index (kg/m2) | 23.6±3.3 | 22.9±3.2 | 23.2±3.2 | 24±3.2 | 24.4±3.4 | <0.001 |
| Overweight, n (%) | 601 (42.3) | 108 (30.8) | 131 (36.4) | 170 (48.2) | 192 (53.9) | <0.001 |
| Hypertension, n (%) | 532 (37.5) | 113 (32.2) | 127 (35.3) | 141 (39.9) | 151 (42.4) | 0.023 |
| Diabetes, n (%) | 221 (15.6) | 56 (15.9) | 55 (15.3) | 57 (16.1) | 53 (14.9) | 0.228 |
| Blood glucose (mmol/L) | 5.2±0.7 | 5.4±1.8 | 5.3±1.7 | 5.3±1.4 | 5.3±1.4 | 0.788 |
| Glycosylated haemoglobin (%) | 5.8±0.5 | 6.1±0.7 | 5.6±0.2 | 5.8±0.5 | 5.7±0.5 | 0.735 |
| Blood urea nitrogen (mmol/L) | 6.0±2.0 | 5.2±1.5 | 5.7±1.5 | 6±1.8 | 7.2±2.6 | <0.001 |
| Serum creatinine (μmol/L) | 80.8±22.4 | 67.7±15.3 | 76.6±14.6 | 82.1±16.6 | 96.6±29.1 | <0.001 |
| eGFR (mL/(min/1.73 m2)) | 86.4±20.6 | 97.3±20.1 | 89.1±18.1 | 84.7±18.5 | 74.7±19.3 | <0.001 |
| eGFR <60 mL/(min/1.73 m2), n (%) | 117 (8.2) | 7 (2.0) | 13 (3.6) | 27 (7.6) | 70 (19.7) | <0.001 |
| Albuminuria, n (%) | 109 (7.7) | 20 (5.7) | 21 (5.8) | 28 (7.9) | 40 (11.2) | <0.001 |
| Cholesterol (mmol/L) | 4±0.9 | 4±0.9 | 4±0.9 | 4±0.9 | 4±0.9 | 0.073 |
| Triglyceride (mmol/L) | 1.3±0.8 | 1.1±0.6 | 1.3±0.7 | 1.5±1 | 1.5±0.9 | <0.001 |
| Low-density lipoprotein cholesterol (mmol/L) | 2.3±0.8 | 2.2±0.8 | 2.2±0.8 | 2.4±0.8 | 2.3±0.8 | 0.132 |
| High-density lipoprotein cholesterol (mmol/L) | 1.2±0.3 | 1.3±0.4 | 1.2±0.3 | 1.1±0.3 | 1.1±0.4 | <0.001 |
| Hyperlipidaemia, n (%) | 292 (20.6) | 36 (10.3) | 68 (18.9) | 86 (24.4) | 102 (28.7) | <0.001 |
| Albumin (g/L) | 40.8±3.9 | 39.1±3.4 | 39.7±3.3 | 40.1±3.6 | 40.4±3.8 | <0.001 |
| Urolithiasis | 76 (5.4) | 15 (4.3) | 22 (6.1) | 20 (5.7) | 19 (5.3) | 0.287 |
| Urinary tract infection | 30 (2.1) | 7 (2.0) | 7 (1.9) | 8 (2.3) | 8 (2.2) | 0.766 |
| Nephrotoxic drugs | 141 (9.9) | 32 (9.1) | 32 (8.9) | 37 (10.5) | 40 (11.2) | 0.021 |
| Low cardiac output syndrome | 178 (12.5) | 33 (9.4) | 36 (10.0) | 46 (13.0) | 63 (17.7) | <0.001 |
Results presented as mean±SD or number (percentage).
eGFR, estimated glomerular filtration rate.
Comparison of AKI incidence and short-term outcomes according to uric acid quartiles
| Q1 (n=351) | Q2 (n=360) | Q3 (n=353) | Q4 (n=356) | P value | |
| AKI, n (%) | 100 (28.5) | 116 (32.2) | 144 (40.8) | 158 (44.4) | <0.001 |
| Severe AKI, n (%) | 21 (6.0) | 26 (7.2) | 28 (7.9) | 33 (9.3) | 0.094 |
| Renal replacement therapy, n (%) | 6 (1.7) | 5 (1.4) | 4 (1.1) | 12 (3.4) | 0.143 |
| Length of hospital stay (days) | 13.5±15.8 | 13.2±6.9 | 13.2±5.1 | 14.2±6.8 | <0.001 |
| Length of intensive care unit stay (hours) | 46.6±80.3 | 46.4±76.4 | 53.1±74.7 | 64.3±116 | <0.001 |
| Poor short-term prognosis, n (%) | 6 (1.7) | 3 (0.8) | 2 (0.6) | 8 (2.2) | 0.613 |
Results presented as mean±SD or number (percentage).
AKI, acute kidney injury.
Figure 1Correlation of uric acid with blood lipid, body mass index and blood glucose.
Figure 2Comparison of acute kidney injury incidence among different subgroups.
Univariate logistic analysis of risk factors for cardiac surgery-associated acute kidney injury
| OR (95% CI) | P value | |
| Gender (male/female) | 1.524 (1.219 to 1.905) | <0.001 |
| Age (1 year added) | 1.022 (1.013 to 1.032) | <0.001 |
| Overweight | 1.403 (1.100 to 1.790) | 0.006 |
| Hypertension | 1.197 (0.959 to 1.495) | 0.113 |
| Diabetes | 1.353 (1.011 to 1.811) | 0.042 |
| Glycosylated haemoglobin | 1.208 (0.779 to 1.983) | 0.365 |
| Coronary angiography | 1.29 (1.039 to 1.602) | 0.021 |
| New York Heart Association grade >II | 1.375 (1.043 to 1.812) | 0.024 |
| Preoperative estimated glomerular filtration rate (<60 mL/(min/1.73 m2)) | 2.016 (1.379 to 2.949) | <0.001 |
| Albuminuria | 1.394 (1.024 to 2.203) | 0.020 |
| Hyperuricaemia | 1.696 (1.275 to 2.022) | <0.001 |
| Hyperlipidaemia | 1.257 (0.896 to 1.636) | 0.098 |
| High-risk surgery | 2.065 (1.538 to 2.772) | <0.001 |
| Cardiopulmonary bypass time (1 min added) | 1.01 (1.007 to 1.014) | <0.001 |
| Aortic occlusion time (1 min added) | 1.015 (1.010 to 1.020) | <0.001 |
| Nephrotoxic drugs | 1.368 (0.889 to 1.958) | 0.064 |
| Low cardiac output syndrome | 2.241 (1.183 to 3.576) | <0.001 |
Multivariate regression analysis of risk factors for cardiac surgery-associated acute kidney injury
| OR (95% CI) | P value | Hosmer-Lemeshow test (P value) | |
| Model 1* | 0.433 | ||
| Male | 1.797 (1.378 to 2.344) | <0.001 | |
| Age | 1.026 (1.014 to 1.038) | <0.001 | |
| Diabetes | 1.681 (1.188 to 2.378) | 0.003 | |
| NYHA grade >II | 1.120 (1.064 to 1.437) | 0.023 | |
| Preoperative eGFR (<60 mL/(min/1.73m2)) | 1.668 (1.071 to 2.598) | 0.024 | |
| High-risk surgery | 1.749 (1.117 to 2.380) | <0.001 | |
| Extracorporeal circulation time | 1.046 (1.012 to 2.362) | <0.001 | |
| Hyperuricaemia | 1.237 (1.095 to 1.885) | 0.009 | |
| Model 2 (model 1+overweight×hyperlipidaemia)† | 0.638 | ||
| Male | 1.892 (1.415 to 2.531) | <0.001 | |
| Age | 1.032 (1.019 to 1.046) | <0.001 | |
| Diabetes | 1.490 (1.002 to 2.215) | 0.047 | |
| Preoperative eGFR (<60 mL/(min/1.73m2)) | 1.741 (1.150 to 2.635) | 0.029 | |
| High-risk surgery | 1.698 (1.134 to 2.459) | 0.013 | |
| Extracorporeal circulation time | 1.009 (1.006 to 1.013) | <0.001 | |
| Overweight×hyperlipidaemia | 1.544 (1.059 to 2.252) | 0.024 | |
| Model 3 (model 1+hyperuricaemia×overweight×hyperlipidaemia)‡ | 0.597 | ||
| Male | 1.658 (1.303 to 2.110) | <0.001 | |
| Age | 1.029 (1.017 to 1.040) | <0.001 | |
| Preoperative eGFR (<60 mL/(min/1.73 m2)) | 1.739 (1.165 to 2.595) | 0.007 | |
| High-risk surgery | 1.779 (1.128 to 2.673) | 0.017 | |
| Extracorporeal circulation time | 1.011 (1.007 to 1.015) | <0.001 | |
| Hyperuricaemia×overweight×hyperlipidaemia | 3.126 (1.731 to 5.646) | <0.001 |
*Covariates adjusted for in model A: male, age, overweight, diabetes, angiography, NYHA grade >II, preoperative eGFR <60 mL/(min/1.73 m2), high-risk surgery, extracorporeal CPB time and aortic occlusion time.
†Covariates adjusted for in model B: male, age, overweight, diabetes, angiography, NYHA grade >II, preoperative eGFR <60 mL/(min/1.73 m2), high-risk surgery, extracorporeal CPB time and aortic occlusion time.
‡Covariates adjusted for in model C: male, age, overweight, diabetes, angiography, NYHA grade >II, preoperative eGFR <60 mL/(min/1.73 m2), high-risk surgery, extracorporeal CPB time and aortic occlusion time.
CPB, cardiopulmonary bypass; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.